Hormone therapy could lower risk of immunotherapy-associated myocarditis in women



Hormone therapy could lower risk of immunotherapy-associated myocarditis in women

A new preclinical study has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.

Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

18th March 2023

New combination of drugs works together to reduce lung tumors in mice

Read more
17th March 2023

Study offers a potential strategy to improve T cell therapy in solid tumors

Read more
17th March 2023

Researchers chart a course for understanding, preventing, and treating young-onset colorectal cancer

Read more